Fibrolamellar Carcinoma News and Research

RSS

Immune cell protein identified as potential target for rare liver cancer treatment

Fibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The disease is caused by a single genetic mutation that creates a fusion protein.

20 Mar 2024

Organoid models provide new scientific insights into a rare childhood liver cancer

Scientists of the Princess Máxima Center for pediatric oncology and Hubrecht Institute in the Netherlands have revealed new scientific insights into the features of fibrolamellar carcinoma (FLC), a rare type of childhood liver cancer

3 May 2023

Gift boosts efforts to understand and combat rare cancers

Curing cancer has been the dream of countless doctors and researchers over the decades. Yet some types of cancer, whether because they affect relatively few people or lack influential advocates, receive less attention and funding than others.

9 Apr 2021

New grant to Harvard Medical School is boosting efforts to understand and combat rare cancers

7 Apr 2021

Researchers pinpoint treatment target for rare liver cancer in adolescents, young adults

New findings show how a genetically aberrant, fused protein promotes a rare form of liver cancer in adolescents and young adults. The researchers also saw that a certain mix of drugs could target the fused protein and the enzymes that it recruits.

10 Jul 2019

CASI reports financial results for second quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, today reported financial results for the three and six months ended June 30, 2015.

14 Aug 2015

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has filed an application with China's Food and Drug Administration to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076.

4 Jun 2015

CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015

15 May 2015

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China, today reported financial results for the three and nine months ended September 30, 2014.

14 Nov 2014

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of hepatocellular carcinoma (HCC).

7 Jul 2014